Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 224.03M P/E - EPS this Y 35.70% Ern Qtrly Grth -
Income -19.8M Forward P/E -9.21 EPS next Y 166.70% 50D Avg Chg -9.00%
Sales 119.25M PEG -0.14 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book N/A EPS next 5Y 70.00% 52W High Chg -37.00%
Recommedations 2.50 Quick Ratio 1.05 Shares Outstanding 175.41M 52W Low Chg 93.00%
Insider Own 2.11% ROA -7.91% Shares Float 148.93M Beta 1.06
Inst Own 63.85% ROE - Shares Shorted/Prior 5.64M/5.17M Price 1.29
Gross Margin 76.00% Profit Margin -16.61% Avg. Volume 2,107,537 Target Price 4.53
Oper. Margin -23.59% Earnings Date Jul 30 Volume 1,422,371 Change -3.01%
About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals, Inc. News
05/23/24 Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
05/10/24 Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
05/10/24 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Analysts Are Pretty Bullish On The Stock After Recent Results
05/08/24 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call Transcript
05/08/24 Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ...
05/07/24 Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
05/07/24 Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
05/02/24 ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04/30/24 Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
04/30/24 Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
04/12/24 Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
04/10/24 Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04/04/24 Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
03/12/24 Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
03/07/24 Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year
03/07/24 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript
03/06/24 Q4 2023 Rigel Pharmaceuticals Inc Earnings Call
03/06/24 Owning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),
03/05/24 Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
03/05/24 Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
RIGL Chatroom

User Image kokooo Posted - 3 minutes ago

$RIGL i like the move we need to get some interest in the company ,rnac agen root all up big after rs, buy it now you wont be able to buy a lot after,

User Image adrum Posted - 14 hours ago

$RIGL at this point the sunk cost fallacy has me locked in. Let’s hope for a “transformative” Monday. Love you all my fellow Riggas.

User Image williams2020 Posted - 1 day ago

$RIGL hate to bring it up for discussion again, but I am truly bewildered by the reverse split decision here, which was proposed when the stock was trading higher. I do not think anyone has really any good explanation for it. With the tavalisse issue almost resolved and rez building, I don't see how this should not be valued higher, but the market is the market. Gavreto remains to be seen whether it can be built up or not. Previously bounced from 0.7s with RR ceo buying shares and a 2nd time with the rez approval. What do you guys think will dig RIGL out of the hole this time? Most reverse splits send shares lower, so I would not be surprised to see this test the lows again before finding any footing. Are they planning on doing the reverse split right away? My best guess is until Rez brings in 10M/quarter and the annora lawsuit settles this could slump a bit in light of the reverse split and dilution threat

User Image MaxKlim Posted - 3 days ago

$RIGL

User Image Baddb Posted - 3 days ago

$VSTM $RIGL $JNJ this 1could get interesting could fall a little more I’m definitely scaling in slowly though ✌️

User Image Lernin_everyday Posted - 3 days ago

$RIGL it seems to me that a substantial and compelling business purpose for the R/S was missing prior to their putting it up for vote and likely influencing the latest drop below $1.00. https://journals.library.wustl.edu/lawreview/article/3738/galley/20571/view/

User Image Caliente44 Posted - 3 days ago

$RIGL If Solit resolution passed, does anyone know date of implementation?

User Image Hanse76 Posted - 3 days ago

$RIGL The day after Memorial Day honoring all the brave men and women who died while serving in the military $RIGL will take off for sure.

User Image DosGatos Posted - 3 days ago

$RIGL Another great week Raul! I bet the sales team just crushed their zoom calls!

User Image kokooo Posted - 3 days ago

$RIGL happy memorial day to all of you stay safe and have great weekend

User Image I_Still_Like_Beer Posted - 3 days ago

$RIGL very happy the r/s was approved. Sets up the perfect short opportunity post-split cheers everyone

User Image kokooo Posted - 3 days ago

$RIGL now lets see if if lily will be pushed to pay higher price.

User Image Cloud875 Posted - 3 days ago

$RIGL was there a re vote on the split with no standard communication?

User Image The_Brand94 Posted - 3 days ago

$RIGL I trimmed my position by half roughly because of the lack of transparency from management. I dont have a lot of confidence in them to do right by investors. The R/S leaves a measure of risk with dilution afterwards. not saying they will, but im just not confident in them looking out for investor interest. I asked why the meeting was delayed and Raul responded with ”to allow for more time for people to vote” .. so thats my opinion. I will have to update my thesis if a R/S is enacted. But market cap wise now with lack of faith in management would be $300M to $400M which represents 2x to 3x from here.

User Image Namhguab Posted - 4 days ago

$RIGL I doubled my position yesterday so forgive me if I become a little uneasy. I try to look at the positives and negatives as well when making decisions. I’m hoping I didn’t miss something in my logical approach to this but it would not be the first time.. we live and learn. Hopefully this is a winner. I do think they need help from a big pharma to really move on. As someone said here; Raul isn’t getting any younger. He may be looking for a payday. Fingers crossed 🤞

User Image kokooo Posted - 4 days ago

$RIGL Guys if you sold, please sincerely leave this message board and never come back, greatly appreciate it .but stop bashing if u sold.

User Image georgeyann Posted - 4 days ago

$RIGL 10K shares!

User Image Berakhot Posted - 4 days ago

$RIGL Presentations in US & EU(June 2024)... https://www.rigel.com/investors/news-events/press-releases/detail/386/rigel-announces-presentations-at-the-upcoming-2024-asco

User Image kokooo Posted - 4 days ago

$RIGL You guys completely forgot about the Anderson deal the government deal the milestone from Lily pharmaceutical, our new drug We just purchased. We have so much going on for us. we are so undervalue look at our market cap in compare to our revenue.

User Image Berakhot Posted - 4 days ago

$RIGL What to watch going forward besides earnings, revenue growth, etc., w/eye on R/s... 1) Analyst ratings 2) Whales adding/selling in future filings Some large whales added shares over last 6mos-1yr. They might be demanding the R/s as some Tutes prefer larger share price. RIGL received 130M votes for R/s. They don't get that w/o Whale approval.

User Image kokooo Posted - 4 days ago

$RIGL one good news this will explode

User Image firepit100 Posted - 4 days ago

$RIGL The unspoken and perhaps unfortunate part about the company's insistence on a RS is that it reveals there is nothing in the works for ex-US collaborations or other alliances for olutasidenib. The company has mentioned this strategic opportunity since it acquired the rights, and it strikes me that if there was something happening in the near term, it could bring in a timely infusion of up-front money, not to mention be a likely driver of improved pps. In the meantime, the company is a) still losing some money each quarter, b) pays out $10m with first dose of Gavreto; c) will start paying on both MD Anderson and CONNECT collaborations. Long story short: management continues failing, over and over, and RS provides an immediate avenue in lieu of 'getting the job done'. On top of that, god knows what Lilly is thinking.

User Image kokooo Posted - 4 days ago

$RIGL our time is now ,forget the past you have real approved drugs now

User Image kokooo Posted - 4 days ago

$RIGL you guys are new to this ints Owens 64% .you are small fish in the sea, c'mon kids look at the big picture some companies with no revenue trading 10 time higher .relax give some time,

User Image kokooo Posted - 4 days ago

$RIGL they gave us chance to buy cheaper the last few weeks .take advantage now.

User Image kokooo Posted - 4 days ago

$RIGL to all the babies crying sell and move on. c'mon .grow some you know what.

User Image DBales26 Posted - 4 days ago

$RIGL Doesn't seem like there's any shares for shorts to cover (or accumulate) and they've used this R/S to continually short and drive the price down. Maybe the BOD and management know what they're doing. I wonder what comes next??

User Image Namhguab Posted - 4 days ago

$RIGL sell the damn company. What a bs way to treat investors on this vote that the fixed. Is this the 2020 election or what? People back getting votes after the vote ends and finding more boxes of proxies sitting around warehouse? Such complete bullshit. They obviously did not have the votes on Wednesday so they found a way to get them.

User Image Berakhot Posted - 4 days ago

$RIGL they're Delaware registered... they're not going to make any illegal moves. If they did, they'd all be in serious trouble. Whatever their reasons R/s is approved by majority votes cast in DE... "Delaware legislature responded to the same market metrics by implementing amendments to reduce the burdens on Delaware chartered corporations. In particular, the Delaware General Corporation Law (“DGCL”) amendments allow for approval by a majority of votes cast (instead of majority of outstanding) and eliminate the class or series shareholder approval requirement if certain conditions are met."

User Image JA_Animalia Posted - 4 days ago

$RIGL Loose-Stool-Raul takes another shit on shareholders.

Analyst Ratings
HC Wainwright & Co. Buy May 8, 24
Citigroup Buy Mar 7, 24
Cantor Fitzgerald Neutral Mar 6, 24
HC Wainwright & Co. Buy Mar 6, 24
B. Riley Securities Neutral Mar 6, 24
HC Wainwright & Co. Buy Feb 22, 24
HC Wainwright & Co. Buy Jan 4, 24
HC Wainwright & Co. Buy Dec 8, 23
HC Wainwright & Co. Buy Aug 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Santos David A EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 02 Sell 1.14 14,519 16,552 349,093 02/06/24
Schorno Dean L EVP & Chief Financia.. EVP & Chief Financial Officer Feb 02 Sell 1.13 12,628 14,270 402,891 02/06/24
RODRIGUEZ RAUL R CEO, President CEO, President Feb 02 Sell 1.14 52,894 60,299 2,036,629 02/06/24
RODRIGUEZ RAUL R CEO, President CEO, President Jun 09 Buy 0.6884 1,000,000 688,400 1,391,776 06/13/22